Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal

Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...